Methylation And Decreased Expression Of 5-Alpha Reductase 2 In Human Prostate Samples: Implications For Resistance To Therapy For BPH
March 2010
in “
The Journal of Urology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This study demonstrated that methylation of the 5-alpha reductase type 2 (5-AR2) promoter is linked to reduced expression of the 5-AR2 protein, possibly explaining resistance to Finasteride in some BPH patients.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the role of 5-alpha reductase type 2 (5-AR2) in resistance to Finasteride therapy for benign prostatic hyperplasia (BPH). In a sample of 21 human prostate tissues, 29% did not express the 5-AR2 protein, and 38% showed methylation in the 5-AR2 promoter region, which correlated with low protein expression. This methylation was linked to resistance to Finasteride, as it inhibits 5-AR2. The study concluded that methylation of the 5-AR2 promoter and subsequent low expression of the protein could explain why some patients are resistant to Finasteride treatment.
